Cargando…

Histopathological diagnoses and patterns in transrectal ultrasound-guided prostatic biopsy series from a large tertiary care center in Saudi Arabia

AIM: The aim of the study was to report our transrectal ultrasound (TRUS)-guided prostatic biopsy histopathological diagnoses and clinical findings in our prostate cancer patients in a tertiary care center. METHODS: We have reviewed our TRUS biopsy series done in our department from January 2011 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsulihem, Ali A., Al-Muaiqel, Muaiqel, Alsunbul, Abdulrahman, Jawhar, Abdulrahman Bin, Al-Dughaiman, Abdullah, Bedaiwi, Khalid K., Al-Rashidi, Sami, Al-Harbi, Faris, El-Tholoth, Hosam S., Al-Hagbani, Mohammad, Milibary, Bader, Alghamdi, Abdullah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210721/
https://www.ncbi.nlm.nih.gov/pubmed/34194133
http://dx.doi.org/10.4103/UA.UA_78_20
Descripción
Sumario:AIM: The aim of the study was to report our transrectal ultrasound (TRUS)-guided prostatic biopsy histopathological diagnoses and clinical findings in our prostate cancer patients in a tertiary care center. METHODS: We have reviewed our TRUS biopsy series done in our department from January 2011 to December 2016. We reviewed our patient's prebiopsy prostate-specific antigen (PSA) findings and the histopathological diagnoses and determined the clinical and pathological features of prostate cancer patients in our series. RESULTS: A total of 398 patients underwent 12 core TRUS biopsies. Benign prostatatic hyperplasia was found in 48.5% of the patients and prostate cancer was found in 113 patients (28.4%). Among them, metastatic prostate cancer was found in 51.7% of them. High Gleason score (8–10) was found in 56.6% and a PSA of more than 20 was found in 63.3% of the patients. CONCLUSION: We recommend a mass public awareness program to encourage our patients to seek early prostate cancer screening and to alert the medical community to encourage more awareness of prostate cancer screening.